Diversified Trust Co Has $504,000 Holdings in Boston Scientific Co. (NYSE:BSX)

Diversified Trust Co lowered its holdings in Boston Scientific Co. (NYSE:BSXFree Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,713 shares of the medical equipment provider’s stock after selling 635 shares during the quarter. Diversified Trust Co’s holdings in Boston Scientific were worth $504,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of BSX. FMR LLC raised its stake in shares of Boston Scientific by 6.8% in the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after acquiring an additional 8,045,263 shares during the last quarter. Vanguard Group Inc. boosted its stake in Boston Scientific by 1.2% in the third quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock valued at $6,534,969,000 after acquiring an additional 1,525,432 shares during the last quarter. State Street Corp raised its position in shares of Boston Scientific by 1.6% during the 2nd quarter. State Street Corp now owns 63,191,897 shares of the medical equipment provider’s stock valued at $3,418,050,000 after acquiring an additional 982,853 shares during the last quarter. Wellington Management Group LLP increased its holdings in Boston Scientific by 5.9% in the third quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock valued at $2,221,641,000 after purchasing an additional 2,336,348 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Boston Scientific by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 26,048,114 shares of the medical equipment provider’s stock valued at $1,404,613,000 after acquiring an additional 718,985 shares during the last quarter. 89.11% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BSX shares. Mizuho raised shares of Boston Scientific from a “neutral” rating to a “buy” rating and boosted their price target for the company from $65.00 to $80.00 in a report on Thursday, February 1st. TD Cowen increased their price objective on shares of Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research note on Thursday, March 7th. Raymond James raised their price target on Boston Scientific from $67.00 to $73.00 and gave the company a “strong-buy” rating in a research note on Thursday, February 1st. Royal Bank of Canada lifted their price objective on shares of Boston Scientific from $67.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Finally, Canaccord Genuity Group upped their price objective on Boston Scientific from $60.00 to $64.00 and gave the company a “buy” rating in a research note on Monday, November 27th. Two analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $66.62.

Read Our Latest Analysis on Boston Scientific

Boston Scientific Stock Performance

NYSE:BSX opened at $67.43 on Thursday. The firm has a market capitalization of $101.15 billion, a PE ratio of 63.02, a price-to-earnings-growth ratio of 2.35 and a beta of 0.78. The company has a quick ratio of 0.82, a current ratio of 1.32 and a debt-to-equity ratio of 0.44. The stock’s 50-day simple moving average is $64.47 and its 200 day simple moving average is $57.56. Boston Scientific Co. has a twelve month low of $47.51 and a twelve month high of $68.07.

Boston Scientific (NYSE:BSXGet Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same period last year, the firm posted $0.45 earnings per share. On average, analysts anticipate that Boston Scientific Co. will post 2.25 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Jeffrey B. Mirviss sold 15,000 shares of the business’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $58.40, for a total transaction of $876,000.00. Following the completion of the sale, the executive vice president now directly owns 56,588 shares of the company’s stock, valued at $3,304,739.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, EVP Jeffrey B. Mirviss sold 15,000 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $58.40, for a total value of $876,000.00. Following the completion of the sale, the executive vice president now directly owns 56,588 shares of the company’s stock, valued at approximately $3,304,739.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jeffrey B. Mirviss sold 15,172 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $59.25, for a total transaction of $898,941.00. Following the transaction, the executive vice president now directly owns 56,588 shares in the company, valued at $3,352,839. The disclosure for this sale can be found here. Insiders have sold a total of 76,460 shares of company stock valued at $4,759,945 over the last ninety days. 0.53% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Articles

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.